Longitudinal omics data and preclinical treatment suggest the proteasome inhibitor carfilzomib as therapy for ibrutinib-resistant CLLLavinia Arseni, Martina Seiffert, Mikhail M. Savitski et al.|Nature Communications|2025Cited by 5